Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Green Tea Found to Kill Leukemia Cells

By HospiMedica staff writers
Posted on 05 Apr 2004
Researchers using laboratory cell cultures have shown that a component of green tea known as epigallocatechin-3 gallate (EGCG) helps kill leukemia cells by interrupting the communication signals needed for them to survive.

The cells studied were from patients with B-cell chronic lymphocytic leukemia (CLL), which is most-often diagnosed in patients in their mid-to-late sixties. More...
Currently, there is no cure, although chemotherapy is administered in severe cases. In the study, green tea's EGCG interrupted survival signals prompted leukemia cells to die in eight of 10 patient samples tested.

While the rationale has been to spare elderly patients exposure to toxic chemotherapy, new tests have improved the ability of doctors to identify early-stage patients who have a more aggressive form of the cancer. As a result, much CLL research is now focused on identifying which initial-stage patients should be treated earlier in the course of the disease, as reported in the February 2004 issue of the journal Blood.

The researchers focused on green tea because epidemiologic studies of cancer have shown that in parts of the world where green tea is consumed, the incidence of solid tumor cancers such as breast, lung, and gastrointestinal cancer is lower. Also, mouse-model testing of the cancer-prevention properties of green tea have shown they protect against solid tumors. In addition, the EGCG component of green tea has been shown in the laboratory to induce death in cancer cells from solid tumors. Research suggests that EGCG works by inhibiting a pathway in the leukemia cells related to angiogenesis.

"We're continuing to look for therapeutic agents that are nontoxic to the patient but kill cancer cells, and this finding with EGCG is an excellent start,” said Neil E. Kay, M.D., of the Mayo Clinic (Rochester, MN, USA).




Related Links:
Mayo Clinic

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.